Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as EVO756
EVO756, Dose 1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose 1 | EXPERIMENTAL | Orally administered EVO756, Dose 1 (Daily) |
| Dose 2 | EXPERIMENTAL | Orally administered EVO756, Dose 2 (Daily) |
| Placebo | PLACEBO_COMPARATOR | Placebo control (Daily) |
| Name | Type | Description |
|---|---|---|
| EVO756, Dose 1 | DRUG | Orally administered EVO756, Dose 1 (Daily) |
| EVO756, Dose 2 | DRUG | Orally administered EVO756, Dose 2 (Daily) |
| Placebo | DRUG | Placebo Control (Daily) |
Key Inclusion Criteria: * Adults aged 18 to \<65 years * Migraine with or without aura, per ICHD-3 criteria * History of failure with prior preventive migraine treatments * Not currently using migraine preventive therapy Key Exclusion Criteria: * Difficulty distinguishing migraine from other head...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 13 | PHASE3 | Atogepant |
| Pfizer Inc. | PFE | 9 | PHASE3 | Rimegepant |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab Dose 1 |
| Ki Health Partners. LLC | RVNC | 1 | - | Daxibotulinumtonix A |
EVO756 is an investigational small molecule being developed for dermatologic and other conditions, including atopic dermatitis, chronic spontaneous urticaria, chronic inducible urticaria, and migraine. It is currently in Phase 2 clinical development and is not approved by the FDA.
EVO756 targets the MRGPRX2 receptor, a G protein-coupled receptor involved in mast cell activation. By modulating this receptor, EVO756 may reduce the release of inflammatory mediators that contribute to conditions like urticaria and atopic dermatitis.
EVO756 is being developed by Evommune, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol EVMN on a public exchange.
EVO756 is in Phase 2 clinical development. It is being evaluated in multiple Phase 2 trials across different indications, including chronic inducible urticaria, chronic spontaneous urticaria, atopic dermatitis, and migraine. It remains an investigational drug and has not received regulatory approval.
EVO756 is being studied in several Phase 2 trials. NCT06603220 evaluates it in chronic inducible urticaria (completed, 30 participants). NCT06873516 is a Phase 2b study in chronic spontaneous urticaria (completed, 182 participants). NCT07150845 is a Phase 2b study in atopic dermatitis (active, not recruiting, 120 participants). NCT07616128 is a study in migraine (recruiting, 330 participants).
Yes, EVO756 is also known as Dose 1. This alternative name may be used in some contexts, but both refer to the same investigational drug being developed by Evommune, Inc.